PE20131034A1 - El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional - Google Patents

El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional

Info

Publication number
PE20131034A1
PE20131034A1 PE2013000084A PE2013000084A PE20131034A1 PE 20131034 A1 PE20131034 A1 PE 20131034A1 PE 2013000084 A PE2013000084 A PE 2013000084A PE 2013000084 A PE2013000084 A PE 2013000084A PE 20131034 A1 PE20131034 A1 PE 20131034A1
Authority
PE
Peru
Prior art keywords
interferon
represented
polyethylene glycol
interferon alpha
positional isomer
Prior art date
Application number
PE2013000084A
Other languages
English (en)
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Angelina Vsevolodovna Klenova
Dmitriy Valentinovich Morozov
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131034(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of PE20131034A1 publication Critical patent/PE20131034A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN CONJUGADO ESTABLE DE INTERFERON-ALFA PEGILADO DE FORMULA (1), DONDE n TIENE VALORES INTEGRALES DE 227 A 10000; m TIENE UN VALOR MAYOR O IGUAL A 4; NALFAH-IFN ES EL INTERFERON ALFA. EL INTERFERON ALFA ES UN INTERFERON a-2b NATURAL O RECOMBINANTE. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO CONJUGADO, ACETATO DE SODIO TRIHIDRATO, ACIDO ACETICO, ENTRE OTROS. DICHO CONJUGADO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES ONCOLOGICAS, VIRALES E INMUNOLOGICAS
PE2013000084A 2010-07-20 2010-09-24 El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional PE20131034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (ru) 2010-07-20 2010-07-20 НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ

Publications (1)

Publication Number Publication Date
PE20131034A1 true PE20131034A1 (es) 2013-09-27

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000084A PE20131034A1 (es) 2010-07-20 2010-09-24 El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional

Country Status (20)

Country Link
KR (1) KR101586372B1 (es)
CN (1) CN102617736B (es)
AR (1) AR087227A1 (es)
BR (1) BRPI1101565A2 (es)
CO (1) CO6680611A2 (es)
CR (1) CR20130021A (es)
CU (1) CU24193B1 (es)
DO (1) DOP2013000002A (es)
EA (1) EA020257B1 (es)
EC (1) ECSP13012398A (es)
HK (1) HK1170504A1 (es)
MX (1) MX2011007458A (es)
MY (1) MY168784A (es)
NI (1) NI201300008A (es)
PE (1) PE20131034A1 (es)
RU (1) RU2447083C1 (es)
SG (1) SG187117A1 (es)
UA (1) UA99766C2 (es)
UY (1) UY33525A (es)
WO (1) WO2012011836A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (ru) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") ГИБРИДНЫЙ БЕЛОК, ОБЛАДАЮЩИЙ ПРОЛОНГИРОВАННЫМ ДЕЙСТВИЕМ, НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА (ВАРИАНТЫ), СПОСОБ ЕГО ПОЛУЧЕНИЯ И ШТАММ Saccharomyces cerevisiae ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА (ВАРИАНТЫ)
EA021643B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
RU2572800C1 (ru) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
EA029498B1 (ru) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b В ВИДЕ МИКРОЧАСТИЦ ДЛЯ ПАРЕНТЕРАЛЬНОГО ПРИМЕНЕНИЯ
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
EP4139343A4 (en) * 2020-04-20 2024-06-12 National Research Council of Canada RECOMBINANT INTERFERON
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
AP2005003246A0 (en) * 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
RU2311930C2 (ru) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Пэгилированный интерферон для борьбы с вирусной инфекцией
JP2008509889A (ja) * 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
DE602006013151D1 (de) * 2005-07-19 2010-05-06 Nektar Therapeutics Verfahren zur herstellung von polymermaleimiden
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
CN101491682A (zh) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101591387A (zh) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 聚乙二醇化重组人干扰素ω偶合物
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
EA201100809A1 (ru) 2012-01-30
RU2010129824A (ru) 2012-01-27
UA99766C2 (uk) 2012-09-25
CU24193B1 (es) 2016-09-30
KR20130056885A (ko) 2013-05-30
CO6680611A2 (es) 2013-05-31
ECSP13012398A (es) 2013-05-31
MX2011007458A (es) 2012-01-19
SG187117A1 (en) 2013-02-28
NI201300008A (es) 2014-05-26
DOP2013000002A (es) 2013-09-15
AR087227A1 (es) 2014-03-12
WO2012011836A1 (en) 2012-01-26
BRPI1101565A2 (pt) 2012-12-04
RU2447083C1 (ru) 2012-04-10
CN102617736B (zh) 2015-11-25
HK1170504A1 (zh) 2013-03-01
UY33525A (es) 2012-02-29
CR20130021A (es) 2013-02-20
KR101586372B1 (ko) 2016-01-18
EA020257B1 (ru) 2014-09-30
CU20130013A7 (es) 2013-04-19
CN102617736A (zh) 2012-08-01
MY168784A (en) 2018-12-04

Similar Documents

Publication Publication Date Title
PE20131034A1 (es) El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
ECSP13012474A (es) Forma de dosificación resistente a manipulación que comprende una sal inorgánica
DOP2012000011A (es) Formulacion farmaceutica
PE20120914A1 (es) Compuestos glucagon activo de receptor de gip
BR112013031268A8 (pt) polipeptídeos
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
CY1113449T1 (el) Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas
ME02015B (me) Farmaceutski preparati sa (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi- 4-metilfenil]-1-tio-D-glucitolom i sekretagogom insulina
BR112014013780A8 (pt) transportador de seringa
BR112015018259A2 (pt) Redução de resposta pró-inflamatória
PE20120204A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
BR112012007990A2 (pt) preparado farmacêutico compreendendo hcg recombinante
ECSP10010516A (es) Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares
EA201290374A1 (ru) Аэрозольная композиция для copd
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
BR112012013199A8 (pt) Composto, composição farmacêutica, e , uso de um composto
RU2014129620A (ru) Композиции, содержащие аморфный эмодепсид
CL2011002213A1 (es) Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras
UA109760C2 (uk) Біологічно активні пептидні комплекси
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer

Legal Events

Date Code Title Description
FC Refusal